New orally available drug for spinal cord injury.
Posted by giorgiobertin on August 11, 2023
New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has demonstrated the safety and tolerability of a new drug treatment designed as a therapeutic intervention for spinal cord injury (SCI).
The research, published in theBritish Journal of Clinical Pharmacology“, found that the drug KCL-286 – which works by activating retinoic acid receptor beta (RARb) in the spine to promote recovery – was well tolerated by participants in a phase 1 clinical trial, with no serious side effects.
These results support further development of KCL-286 as a novel oral treatment for SCI.
“This represents an important first step in demonstrating the feasibility of KCL-286 in the treatment of spinal cord injury. This first human study demonstrated that a 100mg dose delivered via pill can be safely taken by humans. Furthermore, we have also shown that it engages with the correct receptor” – said Jonathan Corcoran, professor of neuroscience and director of the Neuroscience Drug Discovery Unit, at King’s IoPPN.
Read the full text of the article:
Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants
Maria B. Goncalves, Tim Mant, Jörg Täubel, Earl Clarke, Hana Hassanin, Daryl Bendel, Henry Fok, John Posner, Jane Holmes, Adrian P. Mander, Jonathan P. T. Corcoran
Br J Clin Pharmacol. 2023; 1-11. doi:10.1111/bcp.15854
Fonte: Institute of Psychiatry, Psychology & Neuroscience (IoPPN) del King’s College of London
I like:
“Like” Loading…
Related
This entry was posted on agosto 11, 2023 a 6:35 am and is filed under News-ricerca.
Contrassegnato da tag: farmacologia, neurologia. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, oppure trackback from your own site.